The company said revenue for Q2 2025 (3 months) was $3.53 billion ($3.22 billion in the same period a year earlier), diluted EPS was $2.84 ($2.43 a year earlier), and adjusted EPS was $4.35 ($3.94 a year earlier).

1. 01

   The company said revenue for Q2 2025 (3 months) was $3.53 billion ($3.22 billion in the same period a year earlier), diluted EPS was $2.84 ($2.43 a year earlier), and adjusted EPS was $4.35 ($3.94 a year earlier).

2. 02

   Labcorp narrowed its full-year revenue outlook to 7.5% to 8.6% (midpoint raised by 70 basis points), and it gave an adjusted EPS range of $16.05 to $16.50 and a free cash flow range of $1.13 billion to $1.28 billion.

3. 03

   Labcorp said operating cash flow for Q2 (3 months) was $620.6 million, capital expenditures were $77.9 million, and free cash flow was $542.7 million. It cited higher earnings and the timing of capital expenditures as factors behind the increase in free cash flow.

4. 04

   The company said it invested $25.0 million in acquisitions and partnerships during Q2, paid $59.9 million in dividends, and repurchased $200.0 million of its stock.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.